Cite
HARVARD Citation
Broekman, K. et al. (2018). Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer – ESMO-MCBS scores. Cancer treatment reviews. pp. 233-242. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Broekman, K. et al. (2018). Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer – ESMO-MCBS scores. Cancer treatment reviews. pp. 233-242. [Online].